As a result, the 2019 Hellenic Diabetes Association (HAD) guidelines, in alignment with the 2019 American Diabetes Association (ADA) guidelines [24], list SGLT2 inhibitors as the recommended treatment option for DM patients with HF or with atherosclerotic CVD at high risk of HF. Here, SLC5A2 is linked to hydrops fetalis.